Ascribe Capital’s Patterson-UTI PTEN Stock Holding History

Ascribe Capital’s Portfolio PTEN Stock Details PTEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,764,980	Closed	-$31.8M	–	1
2021 Q4	$31.8M	Buy	+3,764,980	New	+$32.4M	59.84%	1

Other funds holding PTEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

KBG

Kahn Brothers Group New York $564M AUM 25.3% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ascribe Capital's PTEN Position: Q1 2022 in Review

Ascribe Capital sold out of Patterson-UTI (PTEN) in Q1 2022, closing a stake of 3,764,980 shares — an estimated $31.8M sold.

Ascribe Capital first reported a position in PTEN in Q4 2021 and held it in 1 quarter. The position peaked at $31.8M in Q4 2021. 271 funds tracked by Wall St. Rank hold PTEN as of Q1 2022.

Ascribe Capital reported no remaining Patterson-UTI position as of Q1 2022 after selling out during the quarter.
Ascribe Capital sold 3,764,980 Patterson-UTI shares in Q1 2022, an estimated $31.8M.
Ascribe Capital first reported a position in Patterson-UTI in Q4 2021 and held it in 1 quarter.
Ascribe Capital's Patterson-UTI position peaked at $31.8M in Q4 2021.
271 funds tracked by Wall St. Rank held Patterson-UTI as of Q1 2022.

Based on Ascribe Capital's 13F filing for Q1 2022.